Zachary J Solomon1, Jorge Rivera Mirabal2, Daniel J Mazur3, Taylor P Kohn4, Larry I Lipshultz5, Alexander W Pastuszak6. 1. Baylor College of Medicine, Houston, TX, USA. 2. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. 3. Urology Associates, Denver, CO, USA. 4. Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Urology Associates, Denver, CO, USA. 6. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: alexander.pastuszak@hsc.utah.edu.
Abstract
INTRODUCTION: Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs. AIM: To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs. METHODS: A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included. MAIN OUTCOME MEASURE: To complete a review of peer-reviewed literature. RESULTS: Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results. CONCLUSION: SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.
INTRODUCTION:Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs. AIM: To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs. METHODS: A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included. MAIN OUTCOME MEASURE: To complete a review of peer-reviewed literature. RESULTS: Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results. CONCLUSION:SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.
Authors: Richard V Clark; Ann C Walker; Susan Andrews; Philip Turnbull; Jeffrey A Wald; Mindy H Magee Journal: Br J Clin Pharmacol Date: 2017-06-10 Impact factor: 4.335
Authors: Scott D Moffat; Alan B Zonderman; E Jeffrey Metter; Marc R Blackman; S Mitchell Harman; Susan M Resnick Journal: J Clin Endocrinol Metab Date: 2002-11 Impact factor: 5.958
Authors: Chris P Miller; Maysoun Shomali; C Richard Lyttle; Louis St L O'Dea; Hillary Herendeen; Kyla Gallacher; Dottie Paquin; Dennis R Compton; Bishwabhusan Sahoo; Sean A Kerrigan; Matthew S Burge; Michael Nickels; Jennifer L Green; John A Katzenellenbogen; Alexei Tchesnokov; Gary Hattersley Journal: ACS Med Chem Lett Date: 2010-12-02 Impact factor: 4.345
Authors: Anthony L Handlon; Lee T Schaller; Lisa M Leesnitzer; Raymond V Merrihew; Chuck Poole; John C Ulrich; Joseph W Wilson; Rodolfo Cadilla; Philip Turnbull Journal: ACS Med Chem Lett Date: 2015-11-19 Impact factor: 4.345